EBMT 2022 | Recent advances in ALL treatment
In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses recent advances in the treatment of acute lymphoblastic leukemia (ALL), focusing on novel immune and cellular therapies. Prof. Mohty first highlights how various immune therapies, such as bispecific T-cell engagers (BiTEs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) like inotuzumab ozogamicin, have transformed the ALL treatment landscape. Prof. Mohty then explains the promising results observed with the use of cellular therapies such as chimeric antigen receptor T-cell (CAR-T) therapy, and the benefit of combining these novel therapies with allogeneic transplantation to improve patient outcomes. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Transcript (edited for clarity)
Until a few years ago, the outcome of acute lymphoblastic leukemia in adults has been quite dismal, especially in situations of high-risk or relapsed/refractory. But all of this has changed, I think, in the last 5 years with the advent of bispecific antibodies, T-cell engagers, namely blinatumomab, which is approved in ALL. With the advent, and the wider use, of TK inhibitors in Philadelphia-positive ALL, but also with the use of antibody-drug conjugates, like inotuzumab...
Until a few years ago, the outcome of acute lymphoblastic leukemia in adults has been quite dismal, especially in situations of high-risk or relapsed/refractory. But all of this has changed, I think, in the last 5 years with the advent of bispecific antibodies, T-cell engagers, namely blinatumomab, which is approved in ALL. With the advent, and the wider use, of TK inhibitors in Philadelphia-positive ALL, but also with the use of antibody-drug conjugates, like inotuzumab. And last, but not least, we’ve seen the impressive results of CAR-Ts, autologous CAR-Ts, targeting CD19 in ALL. And by the way, we will celebrate very soon, the 10th and anniversary of the first patient, Emily Whitehead, receiving these autologous CAR-T for relapsed/refractory ALL.
So now, if you look to ALL in adults, we came from a situation where there were little options beyond, except for conventional key chemotherapies, and now we have immune therapies, whether bispecific antibodies, antibody-drug conjugates, but also cellular therapies like CAR-T. And if you are able, in some patients, to combine this with allotransplant, this is the way that, likely, you will be able to cure more and more of these patients. So it has been a true revolution, I think, in the field of ALL over the last few years.
Read more...
